

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2020/056191 A1

(43) International Publication Date
19 March 2020 (19.03.2020)

(51) International Patent Classification:

A61K 31/341 (2006.01) *A61K 31/4166* (2006.01)
A61K 31/343 (2006.01) *A61K 45/00* (2006.01)
A61K 31/401 (2006.01) *A61P 17/14* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

(21) International Application Number:

PCT/US2019/050890

Published:

— *with international search report (Art. 21(3))*

(22) International Filing Date:

12 September 2019 (12.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/731,076 13 September 2018 (13.09.2018) US

(71) Applicant: **EIRION THERAPEUTICS, INC.** [US/US];
25-K Olympia Ave., Suite 200, Woburn, Massachusetts
01801 (US).

(72) Inventor: **EDELSON, Jonathan**; c/o Eirion Therapeutics,
Inc., 25-K Olympia Ave., Suite 200, Woburn, Massachu-
setts 01801 (US).

(74) Agent: **SUBRAMANIAN, Sowmya** et al.; Choate, Hall &
Stewart LLP, Two International Place, Boston, Massachu-
setts 02110 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS

(57) Abstract: The present disclosures provides surprising insight into new technologies for treatment and/or prevention of certain types of hair loss (also known as alopecia), including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia. Among other things, the present disclosure provides surprising insight that plasminogen activator inhibitor -1 (PAI-1) inhibitors may be surprisingly effective and/or useful in the treatment and/or prevention of certain types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia. Furthermore, the present disclosure provides insight that provided new technologies may not be particularly effective and/or useful in the treatment and/or prevention of other types of alopecia such as radiation-induced alopecia, chemotherapy-induced alopecia, and alopecia due to chronic discoid lupus erythematosus.



WO 2020/056191 A1